RenovaCare, a developer of novel medical-grade liquid spray devices and patented CellMist and SkinGun technologies*, announced favorable outcomes from laboratory studies conducted by Berlin-Brandenburg Center for Regenerative Therapies, a translational research center at Charité-Universitätsmedizin Berlin, one of the world’s largest university hospitals.
“Our goal is to work towards the use of our CellMist and SkinGun technologies to quickly isolate a patient’s own stem cells and gently spray them onto burns and wounds for rapid self-healing,” said Thomas Bold, president and CEO of RenovaCare. “This study’s results provide pre-clinical support for our methodology for first isolating keratinocytes from skin samples, and subsequently achieving even and gentle spray application without harming these powerful yet delicate cells.”
Charité scientists presented their findings from in-vitro studies at the EPUAP Focus Meeting 2016 in Berlin, Germany. Data demonstrated that human skin stem cells sprayed with the company’s patented SkinGun device maintained 97.3% viability. Cell viability is essential to regenerating skin for burns, wounds and cosmetic applications. Cell growth was comparable to pipetting, the industry’s widely accepted “gold-standard” for the deposition of cells.
Among specific aims of the study, one was evaluation of several factors important to the regeneration of human skin, including cell yield, viability, metabolic activity and cell growth. Positive results were reported from experiments related to each of these investigations.
After spraying skin stem cells using the RenovaCare SkinGun, investigators recorded favorable metabolic activity from measurements of glucose consumption and lactate release. Cell morphology was evaluated by microscopic observation, and cell integrity was determined by LDH release.
The study was funded by RenovaCare, and tissue samples for skin cell isolation were obtained from surgical treatments with approval of the Charité ethical committee.
*RenovaCare products are currently in development. They are not available for sale in the U.S. There is no assurance that the company’s planned or filed submissions to the U.S. Food and Drug Administration, if any, will be accepted or cleared by the FDA.